SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRC SciSparc Ltd.

Trading 05-02 13:54:33 EDT

1.34

-0.03

-2.18%

High1.41	Low1.32	Vol55.74K
Open1.40	D1 Closing1.37	Amplitude6.57%
Mkt Cap3.62M	Tradable Cap3.62M	Total Shares2.70M
T/O75.70K	T/O Rate2.07%	Tradable Shares2.70M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SPRC","market":"US","secType":"STK","nameCN":"SciSparc Ltd.","latestPrice":1.3401,"timestamp":1714672158210,"preClose":1.37,"halted":0,"volume":55740,"delay":0,"floatShares":2698605,"shares":2703674,"eps":-14.43,"marketStatus":"Trading","change":-0.0299,"latestTime":"05-02 13:54:33 EDT","open":1.4,"high":1.41,"low":1.32,"amount":75704.03349,"amplitude":0.065693,"askPrice":1.35,"askSize":845,"bidPrice":1.34,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-14.43,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1714680000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.37,"preHourTrading":{"tag":"盘前","latestPrice":1.4001,"preClose":1.37,"latestTime":"08:01 EDT","volume":474,"amount":639.4201224000001,"timestamp":1714651284218},"postHourTrading":{"tag":"盘后","latestPrice":1.38,"preClose":1.37,"latestTime":"19:34 EDT","volume":614,"amount":840.17,"timestamp":1714606452906},"volumeRatio":0.527368},"requestUrl":"/m/hq/s/SPRC","defaultTab":"news","newsList":[{"id":"2427829482","title":"INDO, ONVO and HUSA among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2427829482","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2427829482?lang=en_us&edition=fundamental","pubTime":"2024-04-16 20:28","pubTimestamp":1713270528,"startTime":"0","endTime":"0","summary":"Losers: Ryvyl -37%on launch of proposed underwritten public offering.Pacific Biosciences of California  -16%announces preliminary first Quarter 2024 revenue and updates 2024 revenue guidance.Live Nation Entertainment -9%on reports Justice Dept. may file antitrust lawsuit next month.More on pre-market losers & stocks.  Financial information for Houston American Energy Financial information for Indonesia Energy Financial information for Organovo Holdings Compare metrics for HUSA to INDO, ONVO","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4089998-indo-onvo-and-husa-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":0},{"id":"2426789798","title":"LPCN, ADIL and CADL among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2426789798","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426789798?lang=en_us&edition=fundamental","pubTime":"2024-04-12 20:32","pubTimestamp":1712925165,"startTime":"0","endTime":"0","summary":"Losers: Monogram Orthopaedics (MGRM) -15%.Rallybio Corp (RLYB) -13%.Adial Pharmaceuticals (ADIL) -13%.Lipocine (LPCN) -11%.Bit Origin Ltd (BTOG) -10%.GCT Semiconductor Holding (GCTS) -9%.Eliem Therapeutics (ELYM) -9%.MediaCo Holding (MDIA) -8%.SciSparc Ltd (SPRC) -8%.Candel Therapeutics (CADL) -7%.Applied Digital Corporation APLD-6%after Q3 earnings release.Rent the Runway (RENT) -7%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4089218-lpcn-adil-and-cadl-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":0},{"id":"2426218857","title":"SciSparc Announces Strategic Merger with Automax Motors","url":"https://stock-news.laohu8.com/highlight/detail?id=2426218857","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2426218857?lang=en_us&edition=fundamental","pubTime":"2024-04-12 04:27","pubTimestamp":1712867227,"startTime":"0","endTime":"0","summary":"SciSparc Ltd. (SPRC) has released an update. SciSparc Ltd., an Israeli biomed company, has entered into a definitive merger agreement with Automax ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scisparc-announces-strategic-merger-with-automax-motors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scisparc-announces-strategic-merger-with-automax-motors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2426548012","title":"BRIEF-SciSparc To Acquire Israeli Vehicle Importer AutoMax","url":"https://stock-news.laohu8.com/highlight/detail?id=2426548012","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2426548012?lang=en_us&edition=fundamental","pubTime":"2024-04-11 20:50","pubTimestamp":1712839826,"startTime":"0","endTime":"0","summary":"April 11  - Scisparc Ltd   :   * SCISPARC TO ACQUIRE AUTOMAX   * SCISPARC LTD - WILL ACQUIRE 100% OF AUTOMAX AND ESTABLISH A NEW WHOLLY-OWNED ISRAELI SUBSIDIARY   * SCISPARC LTD - FOLLOWING ACQUISITION SCISPARC SHAREHOLDERS WILL HOLD TOGETHER ABOUT 50.01% OF SHARE CAPITAL OF POST-CLOSING COMBINED COMPANY   * SCISPARC LTD - ALL OUTSTANDING SHARES OF AUTOMAX WILL BE CONVERTED INTO RIGHT TO RECEIVE ORDINARY SHARES OF SCISPARCSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426251882","title":"SciSparc to acquire vehicle importer AutoMax","url":"https://stock-news.laohu8.com/highlight/detail?id=2426251882","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426251882?lang=en_us&edition=fundamental","pubTime":"2024-04-11 20:34","pubTimestamp":1712838846,"startTime":"0","endTime":"0","summary":"SciSparc  said it signed a merger agreement with AutoMax Motors, a vehicle importer company in Israel. As per the deal, the company will acquire 100% of AutoMax and establish a new wholly-owned Israeli subsidiary, which would in turn merge with and into AutoMax.  After the deal SPRC shareholders will hold together ~50.01% of the share capital of the post-closing combined company. Due to the acquisition, all outstanding shares of AutoMax will be converted into the right to receive ordinary shares of SciSparc. After the deal AutoMax’s equity holders are expected to hold together ~49.99% of the combined company’s share capital.   More on SciSparc Ltd.  SciSparc gains on grant of patent for core technology in multiple jurisdictions in Europe SciSparc gains as Clearmind partnership yields 3 new international patent applications Financial information for SciSparc Ltd.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4088884-scisparc-to-acquire-vehicle-importer-automax","is_publish_highlight":false,"gpt_icon":0},{"id":"2426251776","title":"SciSparc to Acquire AutoMax","url":"https://stock-news.laohu8.com/highlight/detail?id=2426251776","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2426251776?lang=en_us&edition=fundamental","pubTime":"2024-04-11 20:15","pubTimestamp":1712837700,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, April 11, 2024  -- SciSparc Ltd.  , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it signed a merger agreement  with AutoMax Motors Ltd. , a leading vehicle importer company in Israel.According to the Agreement, the Company will acquire 100% of AutoMax and establish a new wholly-owned Israeli subsidiary, which would in turn merge with and into AutoMax . Following the Acquisition, it is contemplated that SciSparc shareholders will hold together approximately 50.01% of the share capital of the post-closing combined company .AutoMax is involved in parallel importation and marketing of various private vehicle products in Israel through Global AutoMax. This includes a diverse range of vehicles such as small family cars, crossover vehicles, executive cars, SUVs, premium vehicles, work vehicles, and vehicles adapted for the disabled. Additiona","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-acquire-automax-121500011.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422917881","title":"SciSparc Advances Depression Treatment with New Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2422917881","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2422917881?lang=en_us&edition=fundamental","pubTime":"2024-03-27 23:28","pubTimestamp":1711553301,"startTime":"0","endTime":"0","summary":"SciSparc Ltd. (SPRC) has released an update. SciSparc Ltd., a pharmaceutical company specializing in central nervous system therapies, has announce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scisparc-advances-depression-treatment-with-new-patent?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scisparc-advances-depression-treatment-with-new-patent?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2422991865","title":"BRIEF-Clearmind Submits New International Patent Application For Preventing, Treating Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2422991865","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2422991865?lang=en_us&edition=fundamental","pubTime":"2024-03-27 20:58","pubTimestamp":1711544302,"startTime":"0","endTime":"0","summary":"March 27 (Reuters) - Scisparc Ltd   :   * SCISPARC- CLEARMIND COLLABORATION EVOLVES WITH NEW INTERNATIONAL PATENT APPLICATION FOR PREVENTING AND TREATING DEPRESSIONSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422991257","title":"SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2422991257","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2422991257?lang=en_us&edition=fundamental","pubTime":"2024-03-27 20:55","pubTimestamp":1711544100,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, March 27, 2024  -- SciSparc Ltd.  , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc.    , a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has submitted a patent application under the international Patent Cooperation Treaty.This application was previously filed as a provisional patent application with the United States Patent and Trademark Office .Overall, as part of this collaboration, nine other patent applications have been filed by Clearmind with the USPTO for various compositions, including the composition of SciSparc’s CannAmidewith Clearmind’s MEAI compound for the treatment of alcohol use disorder, cocaine addiction and obesity and its related metaboli","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-clearmind-collaboration-evolves-international-125500357.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421804362","title":"SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2421804362","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2421804362?lang=en_us&edition=fundamental","pubTime":"2024-03-21 20:58","pubTimestamp":1711025880,"startTime":"0","endTime":"0","summary":"MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently. This press release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses that MitoCareX is working towards creating a predictive AI model and that such model is expected to enable MitoCareX to navigate broader chemical spaces more efficiently, with the goal of uncovering more novel anti-cancer scaffolds that target the SLC25 protein of interest. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-mitocarex-unveils-groundbreaking-discovery-125800368.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2420642710","title":"TLRY, ACB and CGC are among pre market gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2420642710","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2420642710?lang=en_us&edition=fundamental","pubTime":"2024-03-18 19:44","pubTimestamp":1710762293,"startTime":"0","endTime":"0","summary":"More on premarket gainers & stock.  Tilray: Big Opportunities Ahead In Germany And Alcohol Segment Aurora Cannabis: Barely Surviving Or Soon To Be Thriving?Canopy Growth Corporation  Q3 2024 Earnings Call Transcript Tilray wins approval for first medical cannabis extract in Portugal Cannabis rescheduling opposed by some DEA officials: WSJ","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4080383-tlry-acb-and-cgc-are-among-pre-market-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2420427103","title":"SciSparc Granted Another Patent, Strengthening its Core Technology in Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2420427103","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2420427103?lang=en_us&edition=fundamental","pubTime":"2024-03-18 19:29","pubTimestamp":1710761340,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, March 18, 2024  -- SciSparc Ltd.  , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has been granted a patent for its core-technology, the combination of cannabinoids and n-acylethanolamines, by the Canadian Intellectual Property Office . The Patent aligns seamlessly with the Company's proprietary technology and is designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits.This patent grant adds to the patent portfolio of the Company, thereby supporting the innovation of SciSparc’s technologies.Oz Adler, CEO of SciSparc, commented, “With this patent, we continue to strengthen our global intellectual property rights. SciSparc is a unique company in the cannabis space. We believe we are building value for our investors, as the Company continues to develop technolo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-granted-another-patent-strengthening-112900184.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2418357945","title":"SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2418357945","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2418357945?lang=en_us&edition=fundamental","pubTime":"2024-03-12 20:14","pubTimestamp":1710245640,"startTime":"0","endTime":"0","summary":"MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently. This press release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses that MitoCareX is working towards creating a predictive AI model and that such model is expected to enable MitoCareX to navigate broader chemical spaces more efficiently, with the goal of uncovering more novel anti-cancer scaffolds that target the SLC25 protein of interest. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and u","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-mitocarex-reveals-promising-results-121400718.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417805163","title":"Samsara, DocuSign, Gap among premarket gainers' pack","url":"https://stock-news.laohu8.com/highlight/detail?id=2417805163","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2417805163?lang=en_us&edition=fundamental","pubTime":"2024-03-08 21:30","pubTimestamp":1709904606,"startTime":"0","endTime":"0","summary":"Ainos  +147%. Psyence Biomedical  +104%. CERo Therapeutics  +47%. Gulf Island Fabrication  +27% on Q4 earnings release. Recruiter.com  +17%. Porch Group  +20% on Q4 earnings release. reAlpha Tech  +18%. Grifols  +17% as auditor clears annual accounts. Quoin Pharmaceuticals  +18%.  Ucommune International  +11%. Samsara  +13% on Q4 earnings release. Ocean Biomedical  +13%. SU Group  +11%. Smith & Wesson Brands  +11% on Q3 earnings release. Treasure Global  +12% after Treasure Global’s AI-powered ZCITY premium store surpasses expectations. Swvl Holdings  +9%. DocuSign  +9% following its upbeat 4Q24 results  QuantaSing Group  +9%. Funko  +8% on Q4 earnings release. Gap  +8% on Q4 earnings release. SoundHound  7%. Regenxbio  7%. SciSparc  6% after FDA status for LSD formulation; announces enrollment of first patient for its clinical trial for children with autism spectrum disorder. See the biggest morning stock movers.","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4077614-samsara-docusign-gap-among-premarket-gainers-pack","is_publish_highlight":false,"gpt_icon":0},{"id":"2417538050","title":"SciSparc Shares Climb After Patient Enrolls in Autism Treatment Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2417538050","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2417538050?lang=en_us&edition=fundamental","pubTime":"2024-03-08 20:39","pubTimestamp":1709901540,"startTime":"0","endTime":"0","summary":"Shares of SciSparc jumped after the first patient was enrolled in a clinical trial for its autism spectrum disorder treatment.The stock was up 17% at $4.21 in premarket trading. Shares had fallen 26% year-to-date when the market closed Thursday.The specialty clinical-stage pharmaceutical company said Friday morning that the trial will assess the efficacy and safety of SCI-210 for the treatment of autism spectrum disorder in children aged 5 to 18.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2417918137","title":"Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2417918137","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2417918137?lang=en_us&edition=fundamental","pubTime":"2024-03-08 00:29","pubTimestamp":1709828952,"startTime":"0","endTime":"0","summary":"Companies focused on psychedelic drugs traded higher on Thursday after Mind Medicine (NASDAQ:MNMD) said that the U.S. FDA issued breakthrough therapy designation for its LSD formulation, MM120 (lyserg","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1446014297/image_1446014297.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1446014297/image_1446014297.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4077271-mind-medicine-sends-psychedelic-stocks-higher-lsd-drug","is_publish_highlight":false,"gpt_icon":0},{"id":"2417793670","title":"BRIEF-SciSparc Granted Patent For Core Technology In Multiple Jurisdictions In Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2417793670","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2417793670?lang=en_us&edition=fundamental","pubTime":"2024-03-07 23:30","pubTimestamp":1709825402,"startTime":"0","endTime":"0","summary":"March 7 (Reuters) - Scisparc Ltd   :   * SCISPARC GRANTED PATENT FOR CORE TECHNOLOGY IN MULTIPLE JURISDICTIONS IN EUROPESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417645897","title":"Rentokil Initial, Avangrid, American Eagle Outfitters among premarket gainers' pack","url":"https://stock-news.laohu8.com/highlight/detail?id=2417645897","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2417645897?lang=en_us&edition=fundamental","pubTime":"2024-03-07 22:09","pubTimestamp":1709820567,"startTime":"0","endTime":"0","summary":"CERo Therapeutics (CERO) +625% after announces publication of preclinical research supporting the use of its clinical candidate CER-1236 to treat AML patients. Lytus Technologies (LYT) +210% after ent","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4077163-rentokil-initial-avangrid-american-eagle-outfitters-among-premarket-gainers-pack","is_publish_highlight":false,"gpt_icon":0},{"id":"2417763575","title":"SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2417763575","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2417763575?lang=en_us&edition=fundamental","pubTime":"2024-03-07 20:49","pubTimestamp":1709815740,"startTime":"0","endTime":"0","summary":"The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key jurisdictions. TEL AVIV, Israel, March 07, 2024  -- SciSparc Ltd.  , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that the process of granting and validation for its core-technology patent has been completed in certain European countries. This patent covers combinations of cannabinoids and n-acylethanolamines . The Patent aligns seamlessly with the Company's proprietary technology designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits.The Patent was granted and validated in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Liechtenstein and the United Kingdom.The invention rela","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-granted-patent-core-technology-124900277.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417223762","title":"SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2417223762","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2417223762?lang=en_us&edition=fundamental","pubTime":"2024-03-07 05:41","pubTimestamp":1709761260,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, March 06, 2024  -- SciSparc Ltd.  , a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today its had been received patent approval for its proprietary combination of opioids and n-acylethanolamines for pain treatment .The Patent has been granted by the Canadian Intellectual Property Office, the government agency in Canada that administers intellectual property rights and legislation for patents.\"With the Canadian patent approval for our opioid reduction technology, SciSparc continues to build on global recognition of its innovations and breakthrough technologies. We are all aware of how effective opiates are in relieving pain, but also for their addictive influence. We believe that our technology will potentially make it possible to improve the therapeutic effect of opiates in lower doses, thereby reducing their addictive potential. Our technology repr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GynGHnbgWjJ4PDu8O8BxhA--~B/aD0yOTY7dz0yOTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/65732aa33e4d792f004f05454b52ba22"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/scisparc-issued-canadian-patent-opioids-214100851.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.scisparc.com","stockEarnings":[{"period":"1week","weight":0.1322},{"period":"1month","weight":-0.2634},{"period":"3month","weight":-0.6215},{"period":"6month","weight":-0.7825},{"period":"1year","weight":-0.9268},{"period":"ytd","weight":-0.7193}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0418},{"period":"3month","weight":0.0228},{"period":"6month","weight":0.1511},{"period":"1year","weight":0.2179},{"period":"ytd","weight":0.0527}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.","exchange":"NASDAQ","name":"SciSparc Ltd.","nameEN":"SciSparc Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SciSparc Ltd.(SPRC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SciSparc Ltd.,SPRC,SciSparc Ltd.股票,SciSparc Ltd.股票老虎,SciSparc Ltd.股票老虎国际,SciSparc Ltd.行情,SciSparc Ltd.股票行情,SciSparc Ltd.股价,SciSparc Ltd.股市,SciSparc Ltd.股票价格,SciSparc Ltd.股票交易,SciSparc Ltd.股票购买,SciSparc Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SciSparc Ltd.(SPRC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SciSparc Ltd.(SPRC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction